Active targeted ligand-aza-BODIPY conjugate for near-infrared photodynamic therapy in melanoma
- 15 April 2020
- journal article
- research article
- Published by Elsevier BV in International Journal of Pharmaceutics
- Vol. 579, 119189
- https://doi.org/10.1016/j.ijpharm.2020.119189
Abstract
Active targeting compound, a non-iodinated derivative of IK-IK-I-2-azaBODIPY (1a) was previously reported to preferentially bind melanoma over healthy cells. In this study, we evaluate the photodynamic therapy (PDT) efficiency on melanoma cells of 1a, together with its reversed sequence compound KI-KI-I-2-azaBODIPY (1b) and a non-targeted control I-2-azaBODIPY-NH2 (2). All three test compounds possess absorption wavelengths in the near-infrared (NIR) region (lambda(max) between 678 and 687 nm) which alleviate melanin interference and allow deeper tissue penetration. In vitro studies revealed 1a and 1b are promising photosensitizers with enhanced singlet oxygen generation, have increased uptake by B16-F10 melanoma cells via clathrin-mediated endocytosis and good photocytotoxic efficacies. Ex vivo biodistribution assays showed both 1a and 1b accumulated in the tumour. In B16-F10 tumour bearing-C57BL/6 mice, 10 mg/kg of 1b and light irradiation was found to reduce tumour volume by up to 23% at day-3. Doubling the dosage of 1b (20 mg/kg) enhanced the antitumour effect, showing 96% maximum tumour volume reduction at day-7 and tumour growth suppression for up to 12 days.Keywords
Funding Information
- Postgraduate Research Grant (PPP) – Research (PG222-2016A)
- Fujian Provincial Natural Science Foundation (2017J01577)
- Thailand Research Fund
- Office of the Higher Education Commission (MRG6180030)
This publication has 84 references indexed in Scilit:
- Melanoma resistance to photodynamic therapy: new insightsBiological Chemistry, 2013
- Targeting PD-1/PD-L1 interactions for cancer immunotherapyOncoImmunology, 2012
- Search for inhibitors of endocytosisCellular Logistics, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Neurotrophins in lung health and diseaseExpert Review of Respiratory Medicine, 2010
- c-Src Is Required for Tropomyosin Receptor Kinase C (TrkC)-induced Activation of the Phosphatidylinositol 3-Kinase (PI3K)-AKT PathwayPublished by Elsevier BV ,2008
- A Combinatorial Method for Solution-Phase Synthesis of Labeled Bivalent β-Turn MimicsJournal of the American Chemical Society, 2007
- In situ photoimmunotherapy: a tumour-directed treatment for melanomaBritish Journal of Dermatology, 2006
- Neurotrophins in Skin Biology and PathologyJournal of Investigative Dermatology, 2006
- A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancerNature Genetics, 2005